David Pomerantz, Chief Commercial Officer at Syapse
Syapse, a real-world evidence company accelerating the delivery of precision medicine through the Syapse Learning Health Network™, today announced the appointment of David Pomerantz as Chief Commercial Officer. In his new role as Chief Commercial Officer, Pomerantz will lead the future direction of Syapse’s commercial endeavors and expand its life sciences partnerships across the Syapse Learning Network.
Pomerantz Bio/Background
Read More
Oncology Technology Solutions, Services Impacting Patients and Providers
Biofourmis Lands $100M to Expand AI-Powered Digital Therapeutics Platform
What You Should Know:
- Boston-based digital therapeutics leader Biofourmis
just closed a $100 million Series C funding round led by SoftBank,
bringing its total funding to $145M.
- Biofourmis will be using the funding to develop, validate and commercialize several released and unreleased digital therapeutics solutions across cardiology, oncology, respiratory, and pain, with a focus on the United States and key Asian markets, including Asia Pacific, China, and
Read More
CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform
What You Should Know:
- CancerIQ raises $5M in Series A funding led by HealthXVentures to accelerate the growth of its genetic cancer risk assessment platform to identify and manage patients at high risk of cancer.
- CancerIQ’s technology enables hospitals to use genomics
to personalize the prevention and early detection of cancer.
- Two new hires recently joined CancerIQ’s newly formed
Integrated Products team from Epic, with the goal of advancing CancerIQ’s
integration with leading
Read More
FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer
What You Should Know:
The FDA and Syapse announce research collaboration expansion
to address urgent public health challenges including supporting FDA’s goal of
rapid understanding of COVID-19.
As part of the research, Syapse is partnering with FDA’s
Oncology Center of Excellence to investigate methods to derive RWD from
multiple sources including electronic health records, registries and molecular
data
Syapse, a real-world
evidence company accelerating the delivery of precision
Read More
M&A Analysis: 3 Benefits of Siemens Healthineers’ $16.4B Acquisition of Varian Medical
What You Should Know:
- Siemens Healthineers and Varian Medical announce a $16.4B deal in an all-cash transaction on 2nd August 2020.
- Deal expected to close in 1H 2021.
- Varian Medical will maintain its brand name and operate “independently”
- Siemens AG will drop holding in Siemens Healthineers from 85% to 72% as part of the transaction.
News of the deal between Siemens Healthineers and Varian Medical will have caught many industry onlookers off guard on Sunday evening.
Read More
COVID-19 Has Permanently Shifted Patient Behavior Towards Virtual Care
What You Should Know:
- The COVID-19 crisis has significantly impacted the
patient care paradigm, and the ripple effects have altered patient behaviors
and expectations, requiring a significant change in how life sciences companies
engage with and support patients
- Accenture surveyed 2700 patients about changes in care
during COVID-19 and found a major shift to virtual care, which patients
embraced.
- Virtual care is here to stay and can be an integral
part of the patient experience
Read More
Brainlab Acquires Medical Video Game Innovator Level Ex
What You Should Know:
- Brainlab, a digital medical technology company based in
Munich, Germany has acquired Level Ex, a digital health startup creating
medical video games designed to advance the clinical skills of physicians and
surgeons.
- The acquisition will accelerate product development, allow Level Ex to enter new clinical areas faster, and expand its footprint in global markets, benefitting more medical professionals across a wider-range of specialties and cases.
- Level Ex
Read More
MD Anderson, Philips Partner on Personalized Oncology Treatments, Clinical Trial Matching
What You Should Know:
- Philips and MD Anderson collaborate to facilitate
personalized oncology treatments and clinical trial matching based on genomic
markers.
- Philips connects oncologists and pathologists around
the world to MD Anderson’s Precision Oncology Decision Support (PODS) system of
actionable clinical information
Philips and The University of Texas MD Anderson Cancer
Center today announced a collaboration to provide oncologists with
evidence-based therapy and clinical
Read More
Backed by Northwell, Conversa Health Raises $12M for AI-Powered Chatbots
What You Should Know:
- Conversa Health raises $12 million in Series B funding
round to expand its AI-powered chatbots enabling health systems, payers and pharmaceutical
companies to engage patients and collect patient-generated health data and
patient-reported outcomes.
- Conversa plans to use the funding to scale its virtual
care and communication platform—97 percent of patients who have used its chatbots
say they can better manage their care with Conversa.
- Murray Brozinsky
Read More
Consumer Genetic Tests Accelerate Precision Medicine for Some Providers
Joel Diamond, MD, FAAFP, Chief Medical Officer at 2bPrecise
Direct-to-consumer (DTC) genetic tests have been on the scene for some time now. The Federal Drug Administration (FDA) approved the first DTC test on three specific BRCA1/BRCA2 breast cancer gene mutations more than two years ago. Six months after that, the agency similarly green-lighted a DTC pharmacogenomic (PGx) test to examine 33 variants for eight different genes that indicate how effectively patients metabolize specific
Read More
